IRBM-Z-1 is a non-competitive inhibitor of Zika virus ( ZIKV ) NS2B-NS3 protease, with an IC50 of 1.8 μM. IRBM-Z-1 also exhibits inhibitory activity against the NS2B-NS3 proteases of T156I-mutated dengue virus 2 ( DENV2 ) and West Nile virus ( WNV ), with IC50 values of 3.9 μM and 4.7 μM, respectively. IRBM-Z-1 inhibits ZIKV replication, attenuates virus-induced cytopathic effects. IRBM-Z-1 is applicable to research related to ZIKV infection [1].
In Vitro, IRBM-Z-1 (72 h) inhibits the replication of ZIKV replicons in stable Vero cells, with an EC50 of 6.0 μM, and shows no cytotoxicity at concentrations up to 32 μM[1]. IRBM-Z-1 (6 days) inhibits the ZIKV-induced cytopathic effect in Vero cells, with an EC50 of 6.25 μM[1].
References:
[1]. Ontoria JM, et al. An allosteric inhibitor of the Zika virus NS2B-NS3 protease with oral efficacy in mouse models. Nat Commun. 2026;17(1):1439. Published 2026 Feb 10.
In Vitro, IRBM-Z-1 (72 h) inhibits the replication of ZIKV replicons in stable Vero cells, with an EC50 of 6.0 μM, and shows no cytotoxicity at concentrations up to 32 μM[1]. IRBM-Z-1 (6 days) inhibits the ZIKV-induced cytopathic effect in Vero cells, with an EC50 of 6.25 μM[1].
References:
[1]. Ontoria JM, et al. An allosteric inhibitor of the Zika virus NS2B-NS3 protease with oral efficacy in mouse models. Nat Commun. 2026;17(1):1439. Published 2026 Feb 10.